{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:28:12Z","timestamp":1788323292268,"version":"build-2803163510"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,8,9]],"date-time":"2020-08-09T00:00:00Z","timestamp":1596931200000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2020,5,28]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Polycystic ovarian syndrome (PCOS) is a common endocrine disorder in women. Women with PCOS have androgen excess as a defining feature. They also have increased insulin resistance and obesity, which are also risk factors for non-alcoholic fatty liver disease (NAFLD). However, published data regarding PCOS as independent risk factor for NAFLD remain controversial. Therefore, we conducted this study to evaluate the association between PCOS and NAFLD using a large national database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified adult female patients (\u226518 years) with PCOS using the National Inpatient Sample database between 2002 and 2014. The control group included patients who did not have a diagnosis of PCOS. Multivariate logistic regression analysis was performed to study the association of NAFLD with PCOS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of a total of 50\u2009785\u2009354 women, 77\u2009415 (0.15%) had PCOS. These patients were younger (32.7 vs 54.8; p&lt;0.001) and more likely to be obese (29.4% vs 8.6%; p&lt;0.001) compared with non-PCOS patients. However, the PCOS group had less hypertension (23.2% vs 39.8%), dyslipidaemia (12% vs 17.8%) and diabetes mellitus (18.1% vs 18.3%) (p&lt;0.001 for all). Using multivariate logistic regression, patients with PCOS had significantly higher rate of NAFLD (OR 4.30, 95%\u2009CI 4.11 to 4.50, p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study showed that patients with PCOS have four times higher risk of developing NAFLD compared with women without PCOS. Further studies are needed to assess if specific PCOS treatments can affect NAFLD progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2019-000352","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T08:59:26Z","timestamp":1597136366000},"page":"e000352","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":51,"title":["Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0059-9538","authenticated-orcid":false,"given":"Mohammad Maysara","family":"Asfari","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology, Medical College of Georgia, Augusta University, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4871-207X","authenticated-orcid":false,"given":"Muhammad Talal","family":"Sarmini","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Baidoun","sequence":"additional","affiliation":[{"name":"Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Al-Khadra","sequence":"additional","affiliation":[{"name":"Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamen","family":"Ezaizi","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Dasarathy","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"McCullough","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"2025073013493786000_7.1.e000352.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.03.020"},{"key":"2025073013493786000_7.1.e000352.2","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/apt.14058","article-title":"Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease","volume":"45","author":"Kim","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025073013493786000_7.1.e000352.3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032046"},{"key":"2025073013493786000_7.1.e000352.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61345-2"},{"key":"2025073013493786000_7.1.e000352.5","doi-asserted-by":"publisher","DOI":"10.1210\/er.2011-1034"},{"key":"2025073013493786000_7.1.e000352.6","doi-asserted-by":"publisher","DOI":"10.1210\/er.2011-1034"},{"key":"2025073013493786000_7.1.e000352.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2006.04.006"},{"key":"2025073013493786000_7.1.e000352.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12978-018-0519-2","article-title":"A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis","volume":"15","author":"Wu","year":"2018","journal-title":"Reprod Health"},{"key":"2025073013493786000_7.1.e000352.9","first-page":"4259","article-title":"Analyses of risk factors for polycystic ovary syndrome complicated with non-alcoholic fatty liver disease","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"key":"2025073013493786000_7.1.e000352.10","doi-asserted-by":"publisher","DOI":"10.3109\/09513590903184084"},{"key":"2025073013493786000_7.1.e000352.11","doi-asserted-by":"publisher","DOI":"10.1038\/nature05488"},{"key":"2025073013493786000_7.1.e000352.12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/cen.12258","article-title":"A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease","volume":"80","author":"Dawson","year":"2014","journal-title":"Clin Endocrinol"},{"key":"2025073013493786000_7.1.e000352.13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12958-016-0173-x","article-title":"Genetic, hormonal and metabolic aspects of PCOS: an update","volume":"14","author":"De Leo","year":"2016","journal-title":"Reprod Biol Endocrinol"},{"key":"2025073013493786000_7.1.e000352.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.10.010"},{"key":"2025073013493786000_7.1.e000352.15","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.23235","article-title":"Are women with polycystic ovarian syndrome at a high risk of non-alcoholic fatty liver disease; a meta-analysis","volume":"14","author":"Ramezani-Binabaj","year":"2014","journal-title":"Hepat Mon"},{"key":"2025073013493786000_7.1.e000352.16","doi-asserted-by":"crossref","unstructured":"Macut D , Bo\u017ei I , Bjeki J , et al . Polycystic ovary syndrome and nonalcoholic fatty liver disease. Eur J Endocrinol 2017:145\u201358.","DOI":"10.1530\/EJE-16-1063"},{"key":"2025073013493786000_7.1.e000352.17","doi-asserted-by":"crossref","first-page":"8351","DOI":"10.3748\/wjg.v20.i26.8351","article-title":"Nonalcoholic fatty liver disease and polycystic ovary syndrome","volume":"20","author":"Vassilatou","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2025073013493786000_7.1.e000352.18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701"},{"key":"2025073013493786000_7.1.e000352.19","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/MEG.0000000000000973","article-title":"The association of nonalcoholic steatohepatitis and obstructive sleep apnea","volume":"29","author":"Asfari","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025073013493786000_7.1.e000352.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.30159.x"},{"key":"2025073013493786000_7.1.e000352.21","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.28055"},{"key":"2025073013493786000_7.1.e000352.22","doi-asserted-by":"crossref","first-page":"e1002542","DOI":"10.1371\/journal.pmed.1002542","article-title":"Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United Kingdom primary care database","volume":"15","author":"Kumarendran","year":"2018","journal-title":"PLoS Med"},{"key":"2025073013493786000_7.1.e000352.23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1382"},{"key":"2025073013493786000_7.1.e000352.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1514916"},{"key":"2025073013493786000_7.1.e000352.25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMcp1514916","article-title":"Clinical practice. polycystic ovary syndrome.","volume":"375","author":"McCartney","year":"2016","journal-title":"N Engl J Med"},{"key":"2025073013493786000_7.1.e000352.26","first-page":"CD005552","article-title":"Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome","author":"Costello","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2025073013493786000_7.1.e000352.27","first-page":"56","article-title":"Metformin use in women with polycystic ovary syndrome","volume":"2","author":"Johnson","year":"2014","journal-title":"Ann Transl Med"},{"key":"2025073013493786000_7.1.e000352.28","first-page":"75","article-title":"Metformin and polycystic ovary syndrome","volume":"1","author":"Yousef","year":"2019","journal-title":"Int J Health Sci"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2019-000352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:49:43Z","timestamp":1753908583000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2019-000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,8,11]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bmjgast-2019-000352"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2019-000352","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}